PLYMOUTH MEETING, Pa., June 12, 2026
Braeburn has announced the presentation of new clinical and real-world research findings for BRIXADI® (buprenorphine) extended-release injection at the 88th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) 2026, reinforcing the growing evidence supporting the treatment of opioid use disorder (OUD) in the evolving fentanyl era. The company will showcase two oral presentations and two scientific posters examining withdrawal suppression, treatment retention, utilization trends, and fentanyl-associated polysubstance use. These findings further expand the clinical understanding of long-acting buprenorphine therapies and their role in addressing one of the most pressing public health challenges facing healthcare systems worldwide. With opioid overdose deaths and fentanyl-related complications continuing to impact communities across the United States, the new data underscore the importance of evidence-based therapies that can improve patient outcomes, enhance treatment adherence, and support long-term recovery.
New Clinical Data Demonstrate Rapid Withdrawal Suppression
One of the featured oral presentations evaluates the relationship between buprenorphine plasma concentrations and withdrawal suppression following administration of weekly and monthly BRIXADI formulations. Researchers conducted a post hoc analysis examining first-dose effects among patients with moderate-to-severe opioid use disorder. The study explored how quickly BRIXADI reduced withdrawal symptoms while also assessing impacts on self-reported illicit opioid use. Findings presented at CPDD 2026 contribute to a growing body of evidence supporting the therapy’s ability to provide rapid and sustained symptom control.
Effective withdrawal management remains a critical factor in treatment initiation and retention, particularly among individuals exposed to high-potency synthetic opioids such as fentanyl. The data provide valuable insights into how extended-release buprenorphine formulations may help address treatment barriers and improve patient engagement during the early stages of recovery.
Real-World Evidence Highlights Improved Treatment Retention
Advertisement
Braeburn will also present a late-breaking real-world analysis comparing treatment retention among patients with opioid use disorder and recent fentanyl use who received BRIXADI versus sublingual buprenorphine therapy. Using electronic medical record data collected over a six-month observation period, investigators assessed the ability of patients to remain engaged in treatment programs. Treatment retention is widely recognized as one of the most important predictors of successful recovery and long-term clinical outcomes.
The study reflects increasing industry focus on generating real-world evidence that complements clinical trial findings and provides a more comprehensive understanding of treatment performance in routine healthcare settings. Additional poster presentations examine utilization trends for weekly and monthly injectable buprenorphine formulations and explore national and regional patterns of fentanyl-associated polysubstance use across the United States between 2016 and 2025.
Expanding Evidence for Long-Acting OUD Treatment Strategies
BRIXADI is approved for the treatment of moderate-to-severe opioid use disorder in patients who have initiated buprenorphine therapy and is intended to be used as part of a comprehensive treatment plan that includes counseling and psychosocial support. The growing body of clinical and real-world evidence presented at CPDD 2026 reflects broader efforts within addiction medicine to develop more effective treatment strategies capable of addressing the complexities of opioid dependence in the fentanyl era. Extended-release injectable therapies offer advantages including sustained medication delivery, reduced dosing burden, and improved treatment adherence compared with daily therapies.
As healthcare providers continue seeking solutions to combat the opioid crisis, data presented by Braeburn contribute valuable scientific insights that may help inform treatment decisions, improve patient outcomes, and strengthen long-term recovery pathways. The company’s research highlights the ongoing importance of innovation, evidence generation, and patient-centered approaches in addressing opioid use disorder and supporting individuals affected by addiction.
Source: Braeburn press release
